Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.

ABSTRACT:

Background

Rosiglitazone and pioglitazone may increase the incidence of fractures. We aimed to determine systematically the risk of fractures associated with thiazolidinedione therapy and to evaluate the effect of the therapy on bone density.

Methods

We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), other trial registries and product information sheets through June 2008. We selected long-term (> or = 1 year) randomized controlled trials involving patients with type 2 diabetes and controlled observational studies that described the risk of fractures or changes in bone density with thiazolidinediones. We calculated pooled odds ratios (ORs) for fractures and the weighted mean difference in bone density.

Results

We analyzed data fr

SUBMITTER: Loke YK 

PROVIDER: S-EPMC2612065 | biostudies-literature | 2009 Jan

REPOSITORIES: biostudies-literature